SCHEMBL4196733

SCHEMBL4196733

COc1ccc(N(Cc2cccnc2)c2ccc(C(=O)O)c(Cl)c2)cc1OC1CCCO1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 4/20 0.44
PDE4B Q07343 3/20 0.44
PDE4C Q08493 2/20 0.44
PDE4D Q08499 2/20 0.44
DHODH Q02127 2/20 0.40
PDK1 Q15118 6/20 0.39
GAA P10253 3/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
PTAFR P25105 1/20 0.38
PDK2 Q15119 1/20 0.38
PDK3 Q15120 1/20 0.38
PDK4 Q16654 1/20 0.38
ACHE P22303 1/20 0.38
MEN1 O00255 1/20 0.37
GLA P06280 1/20 0.37
HPGD P15428 1/20 0.37
KMT2A Q03164 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4193676 0.94 PDE4B (0.42) PDE4APDE4BPDE4CPDE4DDHODH
SCHEMBL4193140 0.90 PDE4B (0.44) PDE4APDE4BPDE4CPDE4DDHODH
SCHEMBL4196752 0.89 PDE4A (0.55) PDE4APDE4BPDE4CPDE4DDHODH
SCHEMBL4193854 0.89 PDE4B (0.48) PDE4APDE4BPDE4CPDE4DGAA
SCHEMBL4195527 0.88 PDE4B (0.41) PDE4APDE4BPDE4CPDE4DDHODH
SCHEMBL1157744 0.87 PDE4B (0.47) PDE4APDE4BPDE4CPDE4DGAA
SCHEMBL1156850 0.86 PDE4A (0.46) PDE4APDE4BPDE4CPDE4DGAA
SCHEMBL4200609 0.86 PDE4B (0.40) PDE4APDE4BPDE4CPDE4DPDK1
SCHEMBL1157495 0.86 PDE4A (0.47) PDE4APDE4BPDE4CPDE4DGAA
SCHEMBL1157475 0.85 PDE4B (0.43) PDE4APDE4BPDE4CPDE4DGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS SCHUMACHER RICHARD A 2009-02-19 US claimed
US-20050119225-A1 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs MEMORY PHARMACEUTICALS CORP. (US) 2005-06-02 US claimed
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS SCHUMACHER RICHARD A 2009-02-19 US disclosed
US-7405230-B2 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs MEMORY PHARMACEUTICALS CORPORATION (US) 2008-07-29 US disclosed
US-20050119225-A1 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs MEMORY PHARMACEUTICALS CORP. (US) 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS PDE4A, PDE4B, PDE3A PDE4A 1/4885PDE4B 2/4885PDE4C 7/4885
US-20050119225-A1 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs PDE4A, PDE4B, PDE3A PDE4A 1/4885PDE4B 2/4885PDE4C 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.